PCC0208009

PCC0208009 is a potent IDO inhibitor with an IC50 value of 4.52 nM in HeLa cell. PCC0208009 alleviates neuropathic pain and comorbidities by regulating synaptic plasticity of anterior cingulate cortex (ACC) and amygdala [1][2].

Product Specifications

CAS Number

[1668565-74-9]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Indoleamine 2,3-Dioxygenase (IDO)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/IDO-IN-2.html

Concentration

10mM

Purity

98.06

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)CN(CC(C)C)C1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1NC(NC4=CC=C(C)C=C4)=O

Molecular Formula

C29H35N7O

Molecular Weight

497.63

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Yu Wang, et al. PCC0208009, an indirect IDO1 inhibitor, alleviates neuropathic pain and co-morbidities by regulating synaptic plasticity of ACC and amygdala. Biochem Pharmacol. 2020 Jul;177:113926.|[2]David K Williams, et al. Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Bioorg Med Chem Lett. 2018 Feb 15;28 (4) :732-736.|[3]Shanyue Sun, et al. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models. Int J Immunopathol Pharmacol. Jan-Dec 2018;32:2058738418787991.